Stockscreener 앱 받기
97.06
0.38%
-0.37
시간 외 거래:
97.00
-0.06
-0.06%
전일 마감가:
$97.43
열려 있는:
$97.21
하루 거래량:
444.60K
Relative Volume:
0.86
시가총액:
$7.63B
수익:
-
순이익/손실:
$-425.38M
주가수익비율:
-16.59
EPS:
-5.8504
순현금흐름:
$-275.21M
1주 성능:
-0.96%
1개월 성능:
-6.73%
6개월 성능:
+26.59%
1년 성능:
+25.13%
1일 변동 폭
$96.03
$98.51
1주일 범위
$96.03
$101.82
52주 변동 폭
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
97.06 | 7.66B | 0 | -425.38M | -275.21M | -5.8504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-12 | 개시 | Canaccord Genuity | Buy |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL) - Yahoo Finance
Cantor Fitzgerald L. P. Makes New $1.95 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026 - Traders Union
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 - PR Newswire
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - AOL.com
Vestal Point Sells Nuvalent Shares: Portfolio Impact and Company OutlookNews and Statistics - IndexBox
Nuvalent (NUVL) Gets a Buy from Canaccord Genuity - The Globe and Mail
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool
Nuvalent's Chief Scientific Officer Sells Over 35,000 Shares - TradingView
Nuvalent (NUVL) CSO sells 35,104 shares after major option exercises - Stock Titan
Nuvalent, Inc. Holdings Raised by HighVista Strategies LLC - National Today
Nuvalent, Inc. $NUVL Holdings Raised by HighVista Strategies LLC - MarketBeat
Farallon Capital Management LLC Sells 147,000 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Braidwell LP Sells 162,894 Shares of Nuvalent, Inc. - National Today
Cantor Fitzgerald L. P. Acquires Shares of 22,500 Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent, Inc. $NUVL Position Increased by Commodore Capital LP - MarketBeat
Braidwell LP Sells 162,894 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Inflation Data: Is Nuvalent Inc forming a bullish divergence2026 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
Is It Time To Reassess Nuvalent (NUVL) After Recent Trial And Pipeline Updates - simplywall.st
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration - Yahoo Finance
25,160 Shares in Nuvalent, Inc. $NUVL Acquired by Jefferies Financial Group Inc. - MarketBeat
Canaccord Genuity Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation - MSN
NUVL: Strong clinical data and rapid enrollment position ROS1 and ALK drugs for global launch - TradingView
(NUVL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
American Century Companies Inc. Sells 11,767 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Growth Value: Should I set a stop loss on Nuvalent IncMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
[144] Nuvalent, Inc. SEC Filing - Stock Titan
Citigroup Inc. Has $3.04 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Aug Sentiment: Will Nuvalent Inc benefit from green energy policiesWeekly Trading Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
HC Wainwright Brokers Lift Earnings Estimates for Nuvalent - MarketBeat
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Moderna (MRNA) and Nuvalent (NUVL) - The Globe and Mail
NUVL: Regulatory filings and commercial launches for ALK and ROS1 NSCLC therapies are on track for 2024 - TradingView
HC Wainwright Brokers Reduce Earnings Estimates for Nuvalent - MarketBeat
NUVLForm S-8Securities to be offered to employees in employee benefit plans - mx.advfn.com
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - mx.advfn.com
TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL - MarketBeat
NUVL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nuvalent Insider Sold Shares Worth $566,788, According to a Recent SEC Filing - marketscreener.com
Nuvalent Executives Sell Shares Under Trading Plan - TradingView
Nuvalent (NUVL) CDO exercises options and sells 5,500 shares under 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CLO sells 5,500 shares after option exercise - Stock Titan
Assessing Nuvalent (NUVL) Valuation After Recent Share Price Cooling And Strong Multi Year Returns - simplywall.st
Nuvalent, Inc. (NUVL) Stock Analysis: A Biotech With A Promising 40.78% Upside Potential - DirectorsTalk Interviews
UBS Adjusts Price Target on Nuvalent to $138 From $132, Maintains Buy Rating - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Barclays Sticks to Their Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Finviz
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):